Literature DB >> 2552914

Oral chemotherapy of fatal B virus (herpesvirus simiae) infection.

H T Zwartouw1, C R Humphreys, P Collins.   

Abstract

Acyclovir and ganciclovir, which were only about 10-fold less effective against B virus than herpes simplex virus type 1 in VERO cells, were tested in vivo in B virus-infected rabbits. Untreated control rabbits became paralysed from 8 days and died from 10 days. Oral acyclovir at a dose rate of 500 mg/kg/day for 21 days prevented death; acyclovir prevented disease at 700 mg/kg/day. In B virus-infected humans such a high dose of acyclovir could not be given by mouth. Nevertheless, high dose oral acyclovir is suggested for immediate prophylaxis when monkey handlers have been exposed to potentially fatal B virus infection. Should signs or symptoms of disease occur then high dose intravenous acyclovir has been recommended. Since ganciclovir was found to be more effective than acyclovir, intravenous ganciclovir might be preferred for the treatment of established infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552914     DOI: 10.1016/0166-3542(89)90037-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

1.  Genistein Has Antiviral Activity against Herpes B Virus and Acts Synergistically with Antiviral Treatments to Reduce Effective Dose.

Authors:  Julia C LeCher; Nga Diep; Peter W Krug; Julia K Hilliard
Journal:  Viruses       Date:  2019-05-31       Impact factor: 5.048

2.  Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus).

Authors:  Lauren A Brush; Darla H Black; Kimberly A Mccormack; Lara K Maxwell; George Wright; Jerry W Ritchey; Mark E Payton; Richard Eberle
Journal:  Comp Med       Date:  2014-10       Impact factor: 0.982

3.  DNA polymerase gene locus of Cercopithecine herpesvirus 1 is a suitable target for specific and rapid identification of viral infection by PCR technology.

Authors:  Manuel Barreto Miranda; Michaela Handermann; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-05       Impact factor: 2.332

Review 4.  Simian herpesviruses and their risk to humans.

Authors:  Ryan D Estep; Ilhem Messaoudi; Scott W Wong
Journal:  Vaccine       Date:  2010-05-26       Impact factor: 3.641

5.  Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds.

Authors:  P W Krug; R F Schinazi; J K Hilliard
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

Review 6.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 7.  Monkey B virus (Cercopithecine herpesvirus 1).

Authors:  David Elmore; Richard Eberle
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

8.  Effective Prophylactic Therapy for Exposure to Monkey B Virus (Macacine alphaherpesvirus 1).

Authors:  Lara K Maxwell; Darla H Black; George E Wright; Melanie A Breshears; Richard Eberle
Journal:  Comp Med       Date:  2019-12-06       Impact factor: 1.565

9.  Decision Tool for Herpes B Virus Antiviral Prophylaxis after Macaque-Related Injuries in Research Laboratory Workers.

Authors:  Sapha Barkati; Hashim Ba Taher; Elizabeth Beauchamp; Cédric P Yansouni; Brian J Ward; Michael D Libman
Journal:  Emerg Infect Dis       Date:  2019-09       Impact factor: 6.883

10.  Understanding Primate Herpesviruses.

Authors:  R Eberle; L Jones-Engel
Journal:  J Emerg Dis Virol       Date:  2017-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.